Skip to main content
SpringerLink
Log in

Fungal Infection

  • Chapter
  • First Online:
The Infectious Diseases Consult Handbook

  • 292 Accesses

Abstract

Unlike prokaryotic bacterial organisms, fungi are eukaryotic and more complex. Species have different life cycles, which can include particularly hardy forms such as spores and conidia. Like bacteria, fungi are ubiquitous in our environment and occupy important roles in different niches. Invasive infection is most common in hosts that have deficits in natural barriers (skin and mucosa) or deficits in immunity. As this book is geared toward the general ID service, there is less emphasis on some of the fungal species seen more commonly in the transplant/immunocompromised populations (Aspergillus, Mucorales, Fusarium, etc.).

In this chapter, we will focus on fungal nomenclature and diagnostics, management of invasive yeast infection, treatment of invasive aspergillosis, management of mucormycosis, and provide a brief overview of common questions regarding endemic fungi.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kidd SE, Abdolrasouli A, Hagen F. Fungal nomenclature: managing change is the name of the Game. Open Forum Infect Dis. 2023;10:ofac559. https://doi.org/10.1093/ofid/ofac559.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mendoza-Reyes DF, Gómez-Gaviria M, Mora-Montes HM. Candida lusitaniae: biology, pathogenicity, virulence factors, diagnosis, and treatment. Infect Drug Resist. 2022;15:5121–35. https://doi.org/10.2147/IDR.S383785.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654–9. https://doi.org/10.1086/432470.

    Article  CAS  PubMed  Google Scholar 

  4. Theel ES, Doern CD. β-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol. 2013;51:3478–83. https://doi.org/10.1128/JCM.01737-13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1-->3)-beta-D-glucan in blood components and release of (1-->3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion. 2002;42:1189–95. https://doi.org/10.1046/j.1537-2995.2002.00162.x.

    Article  CAS  PubMed  Google Scholar 

  6. Lo Cascio G, Koncan R, Stringari G, Russo A, Azzini A, Ugolini A, Ligozzi M, Polati E, Cornaglia G, Concia E, Schweiger V. Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit. Eur J Clin Microbiol Infect Dis. 2015;34:357–65. https://doi.org/10.1007/s10096-014-2239-z.

    Article  CAS  PubMed  Google Scholar 

  7. Egger M, Prüller F, Raggam R, Divjak MK, Kurath-Koller S, Lackner H, Urban C, Strenger V. False positive serum levels of (1-3)-ß-D-glucan after infusion of intravenous immunoglobulins and time to normalisation. J Infect. 2018;76:206–10. https://doi.org/10.1016/j.jinf.2017.10.017.

    Article  CAS  PubMed  Google Scholar 

  8. Kanamori H, Kanemitsu K, Miyasaka T, Ameku K, Endo S, Aoyagi T, Inden K, Hatta M, Yamamoto N, Kunishima H, Yano H, Kaku K, Hirakata Y, Kaku M. Measurement of (1-3)-beta-D-glucan derived from different gauze types. Tohoku J Exp Med. 2009;217:117–21. https://doi.org/10.1620/tjem.217.117.

    Article  CAS  PubMed  Google Scholar 

  9. Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1-->3)-beta-D-glucan concentrations in hemodialysis patients. Nephron. 2001;89:15–9. https://doi.org/10.1159/000046037.

    Article  CAS  PubMed  Google Scholar 

  10. Prattes J, Hoenigl M, Rabensteiner J, Raggam RB, Prueller F, Zollner-Schwetz I, Valentin T, Hönigl K, Fruhwald S, Krause R. Serum 1,3-beta-d-glucan for antifungal treatment stratification at the intensive care unit and the influence of surgery. Mycoses. 2014;57:679–86. https://doi.org/10.1111/myc.12221.

    Article  CAS  PubMed  Google Scholar 

  11. Mennink-Kersten MASH, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis. 2008;46:1930–1. https://doi.org/10.1086/588563.

    Article  PubMed  Google Scholar 

  12. Barton C, Vigor K, Scott R, Jones P, Lentfer H, Bax HJ, Josephs DH, Karagiannis SN, Spicer JF. Beta-glucan contamination of pharmaceutical products: how much should we accept? Cancer Immunol Immunother. 2016;65:1289–301. https://doi.org/10.1007/s00262-016-1875-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ito S, Ashizawa M, Sasaki R, Ikeda T, Toda Y, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Fujiwara S-I, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Suzuki J, Hatakeyama S, Morisawa Y, Yamada T, Kanda Y. False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G. J Infect Chemother. 2018;24:812–4. https://doi.org/10.1016/j.jiac.2018.06.008.

    Article  CAS  PubMed  Google Scholar 

  14. Agnelli C, Bouza E, del Carmen Martínez-Jiménez M, Navarro R, Valerio M, Machado M, Guinea J, Sánchez-Carrillo C, Alonso R, Muñoz P, for the Collaborative Group on Mycosis (COMIC) Study Group. Clinical relevance and prognostic value of persistently negative (1,3)-β-D-glucan in adults with Candidemia: a 5-year experience in a tertiary hospital. Clin Infect Dis. 2020;70:1925–32. https://doi.org/10.1093/cid/ciz555.

    Article  CAS  PubMed  Google Scholar 

  15. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172–7. https://doi.org/10.1086/378745.

    Article  PubMed  Google Scholar 

  16. Lee RA, Zurko JC, Camins BC, Griffin RL, Rodriguez JM, McCarty TP, Magadia J, Pappas PG. Impact of infectious disease consultation on clinical management and mortality in patients with Candidemia. Clin Infect Dis. 2019;68:1585–7. https://doi.org/10.1093/cid/ciy849.

    Article  PubMed  Google Scholar 

  17. Mohr A, Simon M, Joha T, Hanses F, Salzberger B, Hitzenbichler F. Epidemiology of candidemia and impact of infectious disease consultation on survival and care. Infection. 2020;48:275–84. https://doi.org/10.1007/s15010-020-01393-9.

    Article  PubMed  Google Scholar 

  18. Nunes CZ, Marra AR, Edmond MB, da Silva VE, Pereira CAP. Time to blood culture positivity as a predictor of clinical outcome in patients with Candida albicans bloodstream infection. BMC Infect Dis. 2013;13:486. https://doi.org/10.1186/1471-2334-13-486.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hedderwick SA, Lyons MJ, Liu M, Vazquez JA, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit. Eur J Clin Microbiol Infect Dis. 2000;19:663–70. https://doi.org/10.1007/s100960000348.

    Article  CAS  PubMed  Google Scholar 

  20. Leroy G, Lambiotte F, Thévenin D, Lemaire C, Parmentier E, Devos P, Leroy O. Evaluation of “Candida score” in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care. 2011;1:50. https://doi.org/10.1186/2110-5820-1-50.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Timsit J-F, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet J-L, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou J-C, Foucrier A, Allaouchiche B, Das V, Gangneux J-P, Ruckly S, Maubon D, Jullien V, Wolff M, EMPIRICUS Trial Group. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA. 2016;316:1555–64. https://doi.org/10.1001/jama.2016.14655.

    Article  CAS  PubMed  Google Scholar 

  22. Zhang AY, Shrum S, Williams S, Petnic S, Nadle J, Johnston H, Barter D, Vonbank B, Bonner L, Hollick R, Marceaux K, Harrison L, Schaffner W, Tesini BL, Farley MM, Pierce RA, Phipps E, Mody RK, Chiller TM, Jackson BR, Vallabhaneni S. The changing epidemiology of Candidemia in the United States: injection drug use as an increasingly common risk factor-active surveillance in selected sites, United States, 2014-2017. Clin Infect Dis. 2020;71:1732–7. https://doi.org/10.1093/cid/ciz1061.

    Article  PubMed  Google Scholar 

  23. Poowanawittayakom N, Dutta A, Stock S, Touray S, Ellison RT, Levitz SM. Reemergence of intravenous drug use as risk factor for Candidemia, Massachusetts, USA. Emerg Infect Dis. 2018;24:631–7. https://doi.org/10.3201/eid2404.171807.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Newton-John HF, Wise K, Looke DF. Role of the lemon in disseminated candidiasis of heroin abusers. Med J Aust. 1984;140:780–1. https://doi.org/10.5694/j.1326-5377.1984.tb132597.x.

    Article  CAS  PubMed  Google Scholar 

  25. Sankar NP, Thakarar K, Rokas KE. Candida infective endocarditis during the infectious diseases and substance use disorder syndemic: a six-year case series. Open Forum Infect Dis. 2020;7:ofaa142. https://doi.org/10.1093/ofid/ofaa142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–50. https://doi.org/10.1093/cid/civ933.

    Article  PubMed  Google Scholar 

  27. Jung P, Mischo CE, Gunaratnam G, Spengler C, Becker SL, Hube B, Jacobs K, Bischoff M. Candida albicans adhesion to central venous catheters: impact of blood plasma-driven germ tube formation and pathogen-derived adhesins. Virulence. 2020;11:1453–65. https://doi.org/10.1080/21505594.2020.1836902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Janum S, Afshari A. Central venous catheter (CVC) removal for patients of all ages with candidaemia. Cochrane Database Syst Rev. 2016;7:CD011195. https://doi.org/10.1002/14651858.CD011195.pub2.

    Article  PubMed  Google Scholar 

  29. Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, Garnacho-Montero J, Kanj SS, Machado FR, Montravers P, Sakr Y, Sanguinetti M, Timsit J-F, Bassetti M. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45:789–805. https://doi.org/10.1007/s00134-019-05599-w.

    Article  PubMed  Google Scholar 

  30. Fernández-Cruz A, Cruz Menárguez M, Muñoz P, Pedromingo M, Peláez T, Solís J, Rodríguez-Créixems M, Bouza E, GAME Study Group (Grupo de Apoyo al Manejo de la Endocarditis). The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort. Eur J Clin Microbiol Infect Dis. 2015;34:1543–9. https://doi.org/10.1007/s10096-015-2384-z.

    Article  PubMed  Google Scholar 

  31. Foong KS, Sung A, Burnham JP, Kronen R, Lian Q, Salazar Zetina A, Hsueh K, Lin C, Powderly WG, Spec A. Risk factors predicting Candida infective endocarditis in patients with candidemia. Med Mycol. 2020;58:593–9. https://doi.org/10.1093/mmy/myz104.

    Article  PubMed  Google Scholar 

  32. Breazzano MP, Bond JB, Bearelly S, Kim DH, Donahue SP, Lum F, Olsen TW. American Academy of Ophthalmology recommendations on screening for endogenous candida endophthalmitis. Ophthalmology. 2022;129:73–6. https://doi.org/10.1016/j.ophtha.2021.07.015.

    Article  PubMed  Google Scholar 

  33. Seidelman J, Fleece M, Bloom A, Lydon E, Yang W, Arnold C, Weber DJ, Okeke NL. Endogenous Candida endophthalmitis: who is really at risk? J Infect. 2021;82:276–81. https://doi.org/10.1016/j.jinf.2020.12.032.

    Article  PubMed  Google Scholar 

  34. Caccese R, Carfagna P, Pistilli N, Massetti AP, Falcone M, Venditti M. Candidal thrombophlebitis of central veins: case report and review. Med Mycol. 2012;50:299–304. https://doi.org/10.3109/13693786.2011.604046.

    Article  PubMed  Google Scholar 

  35. Block AA, Thursky KA, Worth LJ, Slavin MA. Thrombolytic therapy for management of complicated catheter-related Candida albicans thrombophlebitis. Intern Med J. 2009;39:61–3. https://doi.org/10.1111/j.1445-5994.2008.01867.x.

    Article  CAS  PubMed  Google Scholar 

  36. Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother. 2005;55:312–6. https://doi.org/10.1093/jac/dki020.

    Article  CAS  PubMed  Google Scholar 

  37. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. Risk of fungemia due to rhodotorula and antifungal susceptibility testing of rhodotorula isolates. J Clin Microbiol. 2003;41:5233–5. https://doi.org/10.1128/JCM.41.11.5233-5235.2003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Thompson GR, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother. 2009;64:79–83. https://doi.org/10.1093/jac/dkp138.

    Article  CAS  PubMed  Google Scholar 

  39. Guinea J, Recio S, Escribano P, Peláez T, Gama B, Bouza E. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob Agents Chemother. 2010;54:4012–5. https://doi.org/10.1128/AAC.00685-10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Perlin DS. Echinocandin resistance in candida. Clin Infect Dis. 2015;61(Suppl 6):S612–7. https://doi.org/10.1093/cid/civ791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Fernández-Ruiz M, Aguado JM, Almirante B, Lora-Pablos D, Padilla B, Puig-Asensio M, Montejo M, García-Rodríguez J, Pemán J, Ruiz Pérez de Pipaón M, Cuenca-Estrella M, CANDIPOP Project, GEIH-GEMICOMED (SEIMC), REIPI. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis. 2014;58:1413–21. https://doi.org/10.1093/cid/ciu158.

    Article  CAS  PubMed  Google Scholar 

  42. Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216:S445–51. https://doi.org/10.1093/infdis/jix131.

    Article  CAS  PubMed  Google Scholar 

  43. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen M-H, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322. https://doi.org/10.1086/649858.

    Article  PubMed  Google Scholar 

  44. Ahmad S, Alfouzan W. Candida auris: epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms. 2021;9:807. https://doi.org/10.3390/microorganisms9040807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27:68–88. https://doi.org/10.1128/CMR.00046-13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49(Suppl 1):7–10. https://doi.org/10.1093/jac/49.suppl_1.7.

    Article  CAS  PubMed  Google Scholar 

  47. Greene RE, Schlamm HT, Oestmann J-W, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, de Pauw BE, Rubin RH. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–9. https://doi.org/10.1086/509917.

    Article  PubMed  Google Scholar 

  48. Ray A, Mittal A, Vyas S. CT halo sign: a systematic review. Eur J Radiol. 2020;124:108843. https://doi.org/10.1016/j.ejrad.2020.108843.

    Article  PubMed  Google Scholar 

  49. Huang Y-T, Hung C-C, Liao C-H, Sun H-Y, Chang S-C, Chen Y-C. Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol. 2007;45:2858–62. https://doi.org/10.1128/JCM.00050-07.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–27. https://doi.org/10.1086/503427.

    Article  CAS  PubMed  Google Scholar 

  51. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT, Bacigalupo A. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis. 2004;38:913–6. https://doi.org/10.1086/382224.

    Article  PubMed  Google Scholar 

  52. Guigue N, Menotti J, Ribaud P. False positive galactomannan test after ice-pop ingestion. N Engl J Med. 2013;369:97–8. https://doi.org/10.1056/NEJMc1210430.

    Article  CAS  PubMed  Google Scholar 

  53. Vergidis P, Razonable RR, Wheat LJ, Estes L, Caliendo AM, Baden LR, Wingard JR, Baddley J, Assi M, Norris S, Chandrasekar P, Shields R, Nguyen H, Freifeld A, Kohler R, Kleiman M, Walsh TJ, Hage CA. Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. J Clin Microbiol. 2014;52:2199–201. https://doi.org/10.1128/JCM.00285-14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Weisser M, Rausch C, Droll A, Simcock M, Sendi P, Steffen I, Buitrago C, Sonnet S, Gratwohl A, Passweg J, Fluckiger U. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis. 2005;41:1143–9. https://doi.org/10.1086/444462.

    Article  CAS  PubMed  Google Scholar 

  55. Zou M, Tang L, Zhao S, Zhao Z, Chen L, Chen P, Huang Z, Li J, Chen L, Fan X. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One. 2012;7:e43347. https://doi.org/10.1371/journal.pone.0043347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young J-AH, Bennett JE. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–e60. https://doi.org/10.1093/cid/ciw326.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Wahla AS, Chatterjee A, Khan II, Conforti JF, Haponik E. Survey of academic pulmonologists, oncologists, and infectious disease physicians on the role of bronchoscopy in managing hematopoietic stem cell transplantation patients with pulmonary infiltrates. J Bronchol Interv Pulmonol. 2014;21:32–9. https://doi.org/10.1097/LBR.0000000000000042.

    Article  Google Scholar 

  58. Heo ST, Tatara AM, Jiménez-Ortigosa C, Jiang Y, Lewis RE, Tarrand J, Tverdek F, Albert ND, Verweij PE, Meis JF, Mikos AG, Perlin DS, Kontoyiannis DP. Changes in in vitro susceptibility patterns of Aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center, 1999-2015. Clin Infect Dis. 2017;65:216. https://doi.org/10.1093/cid/cix297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–15. https://doi.org/10.1056/NEJMoa020191.

    Article  CAS  PubMed  Google Scholar 

  60. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee D-G, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann A-H, Zeiher B, Ullmann AJ. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–9. https://doi.org/10.1016/S0140-6736(15)01159-9.

    Article  CAS  PubMed  Google Scholar 

  61. Maertens JA, Rahav G, Lee D-G, Ponce-de-León A, Sánchez ICR, Klimko N, Sonet A, Haider S, Vélez JD, Raad I, Koh L-P, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397:499–509. https://doi.org/10.1016/S0140-6736(21)00219-1.

    Article  CAS  PubMed  Google Scholar 

  62. Slavin MA, Chen Y-C, Cordonnier C, Cornely OA, Cuenca-Estrella M, Donnelly JP, Groll AH, Lortholary O, Marty FM, Nucci M, Rex JH, Rijnders BJA, Thompson GR, Verweij PE, White PL, Hargreaves R, Harvey E, Maertens JA. When to change treatment of acute invasive aspergillosis: an expert viewpoint. J Antimicrob Chemother. 2021;77:16–23. https://doi.org/10.1093/jac/dkab317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of Mucormycosis: an update. J Fungi (Basel). 2020;6:265. https://doi.org/10.3390/jof6040265.

    Article  CAS  PubMed  Google Scholar 

  64. Cornely OA, Alastruey-Izquierdo A, Arenz D, SCA C, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, AMS A-H, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel C-P, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee D-G, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, MJGT V, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A, Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405–21. https://doi.org/10.1016/S1473-3099(19)30312-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Palejwala SK, Zangeneh TT, Goldstein SA, Lemole GM. An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis. Surg Neurol Int. 2016;7:61. https://doi.org/10.4103/2152-7806.182964.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Gupta MK, Kumar N, Dhameja N, Sharma A, Tilak R. Laboratory diagnosis of mucormycosis: present perspective. J Family Med Prim Care. 2022;11:1664–71. https://doi.org/10.4103/jfmpc.jfmpc_1479_21.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–9. https://doi.org/10.1086/590004.

    Article  PubMed  Google Scholar 

  68. Smith C, Lee SC. Current treatments against mucormycosis and future directions. PLoS Pathog. 2022;18:e1010858. https://doi.org/10.1371/journal.ppat.1010858.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Wheat LJ. Approach to the diagnosis of the endemic mycoses. Clin Chest Med. 2009;30:379–89, viii. https://doi.org/10.1016/j.ccm.2009.02.011.

    Article  PubMed  Google Scholar 

  70. Basso RP, Poester VR, Benelli JL, Stevens DA, Xavier MO. Disseminated histoplasmosis in persons with HIV/AIDS, southern Brazil, 2010–2019. Emerg Infect Dis. 2022;28:721–4. https://doi.org/10.3201/eid2803.212150.

    Article  PubMed  PubMed Central  Google Scholar 

  71. de Perio MA, Benedict K, Williams SL, Niemeier-Walsh C, Green BJ, Coffey C, Di Giuseppe M, Toda M, Park J-H, Bailey RL, Nett RJ. Occupational histoplasmosis: epidemiology and prevention measures. J Fungi (Basel). 2021;7:510. https://doi.org/10.3390/jof7070510.

    Article  PubMed  Google Scholar 

  72. Joseph Wheat L. Current diagnosis of histoplasmosis. Trends Microbiol. 2003;11:488–94. https://doi.org/10.1016/j.tim.2003.08.007.

    Article  CAS  PubMed  Google Scholar 

  73. Azar MM, Hage CA. Laboratory diagnostics for histoplasmosis. J Clin Microbiol. 2017;55:1612–20. https://doi.org/10.1128/JCM.02430-16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, Williams PL, Infectious Diseases Society of America. Coccidioidomycosis. Clin Infect Dis. 2005;41:1217–23. https://doi.org/10.1086/496991.

    Article  PubMed  Google Scholar 

  75. Williams SL, Chiller T. Update on the epidemiology, diagnosis, and treatment of Coccidioidomycosis. J Fungi (Basel). 2022;8:666. https://doi.org/10.3390/jof8070666.

    Article  CAS  PubMed  Google Scholar 

  76. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, Johnson RH, Kusne S, Lisse J, MacDonald JD, Meyerson SL, Raksin PB, Siever J, Stevens DA, Sunenshine R, Theodore N. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e112–46. https://doi.org/10.1093/cid/ciw360.

    Article  PubMed  Google Scholar 

  77. Saccente M, Woods GL. Clinical and laboratory update on Blastomycosis. Clin Microbiol Rev. 2010;23:367–81. https://doi.org/10.1128/CMR.00056-09.

    Article  PubMed  PubMed Central  Google Scholar 

  78. McBride JA, Gauthier GM, Klein BS. Clinical manifestations and treatment of blastomycosis. Clin Chest Med. 2017;38:435–49. https://doi.org/10.1016/j.ccm.2017.04.006.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America—PubMed. https://pubmed-ncbi-nlm-nih-gov.treadwell.idm.oclc.org/18462107/. Accessed 27 Feb 2023.

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

    Alexander M. Tatara

Authors
  1. Alexander M. Tatara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander M. Tatara .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tatara, A.M. (2023). Fungal Infection. In: The Infectious Diseases Consult Handbook. Springer, Cham. https://doi.org/10.1007/978-3-031-39474-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-39474-4_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-39473-7

  • Online ISBN: 978-3-031-39474-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation